TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05951790

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle Training (IMT) + Air Stacking
Description: Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in, along with Air Stacking (AS). AS is a lung insufflation method that requires the use of a manual insufflator to provide air volumes higher than inspiratory capacity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) + Air Stacking
Description: Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in, along with Air Stacking (AS). AS is a lung insufflation method that requires the use of a manual insufflator to provide air volumes higher than inspiratory capacity
Study: NCT05931276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties
Study: NCT05715281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given IV
Study: NCT05684484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 MCG Oral Tablet [DALIRESP]
Description: Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: amino salicylic acid
Description: conventional treatment
Study: NCT06360354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Description: Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV
Study: NCT05372484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal optical imaging
Description: Women referred for colposcopy due to abnormal cervical screening will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
Study: NCT05969483

Intervention type: DEVICE
Intervention: pEEG monitoring
Description: pEEG monitoring during PICU admission
Study: NCT05883436

Intervention type: DEVICE
Group type: OTHER
Intervention: DEXA-C Cervical Interbody System
Description: The Dexa-C Cervical Interbody System is intended for use on patients who require anterior cervical discectomy and fusion surgery. The system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate
Study: NCT06651060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will view a sample of items from a restaurant menu, displayed with labels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will view a sample of items from a restaurant menu, displayed with labels

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Menu label
Description: Participants will view a sample of items from a restaurant menu, displayed with labels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will view a sample of items from a restaurant menu, displayed with labels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will view a sample of items from a restaurant menu, displayed with labels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will view a sample of items from a restaurant menu, displayed with labels
Study: NCT04724499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Intervals Training
Description: 16 week exercise program with stationary bike.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: 16 week stretching program.
Study: NCT06297226

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arlocabtagene Autoleucel (BMS-986393)
Description: Specified dose on specified days
Study: NCT06651476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: Oxytocin 10 IU will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
Study: NCT06650267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers for Change (F4C)
Description: Defining features of F4C delivered over 18 sessions: 1) focus on the fathers model of fatherhood as a motivator for change, 2) focus on understanding and identifying feelings, teaching skills to identify and change emotional dysregulation that lead to both SU and FV, 3) co-parent communication skills to reduce stress and improve problem solving, 4) restorative parenting (see Table 1 and figure 1)127. F4C focuses on reflective understanding of emotional experiences, how that impacts thoughts and behaviors related to SU, FV, co-parenting/parenting each session. Through greater self-awareness, the father is better able to apply coping, communication and parenting skills introduced to reduce SU and FV.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Drug Counseling (IDC)
Description: IDC is an individual evidence-based SU treatment84 that incorporates two elements: endorsement of the disease model and the spiritual dimensions of recovery. These elements differentiate the approach from F4C. IDC is influenced by 12-step recovery philosophy and participation in 12-step groups like NA are encouraged. The model places focus on the individual in recovery without a focus on fatherhood or co-parenting. IDC will be offered in an 18-session format.
Study: NCT06651333

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task, Drug cue task, and Cognitive behavioral therapy task. Participants are not presented with any specific stimulus.

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task, Drug cue task, and Cognitive behavioral therapy task. Participants are not presented with any specific stimulus.
Study: NCT04856085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFNα
Description: PEG-IFNα given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFNα
Description: PEG-IFNα given by subcutaneous injection
Study: NCT05405205

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: synbiotic
Description: Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in drinking water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, maltodextrin, sucralose and flavour twice a day resolved in drinking water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in drinking water
Study: NCT04697524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Virtual group meetings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Virtual group meetings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Management Service (SMS) Consultation
Description: Virtual individual meetings with symptom management service (SMS) over 5 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Management Service (SMS) Consultation
Description: Virtual individual meetings with symptom management service (SMS) over 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) Questionnaires
Description: Administered at each study visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) Questionnaires
Description: Administered at each study visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Virtual exit interview at end of study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Virtual exit interview at end of study
Study: NCT06179004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 133mg Liposomal bupivacaine plus 10mL 0.5% bupivacaine administered in a supraclavicular single shot perineural injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20mL 0.25% bupivacaine administered in a supraclavicular single shot perineural injection
Study: NCT06380309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDOV-SAFE
Description: Intravenous injection of oncolytic virus concomitant with Triprolizumab and fruquintinib every 3 weeks until tumor progression

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDOV-SAFE
Description: Intravenous injection of oncolytic virus concomitant with Triprolizumab and fruquintinib every 3 weeks until tumor progression

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDOV-SAFE
Description: Intravenous injection of oncolytic virus concomitant with Triprolizumab and fruquintinib every 3 weeks until tumor progression

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDOV-SAFE
Description: Intravenous injection of oncolytic virus concomitant with Triprolizumab and fruquintinib every 3 weeks until tumor progression

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDOV-SAFE
Description: Intravenous injection of oncolytic virus concomitant with Triprolizumab and fruquintinib every 3 weeks until tumor progression

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDOV-SAFE
Description: Intravenous injection of oncolytic virus concomitant with Triprolizumab and fruquintinib every 3 weeks until tumor progression
Study: NCT04856085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFNα
Description: PEG-IFNα given by subcutaneous injection
Study: NCT05161000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement
Description: ONS plus dietary counseling
Study: NCT06365216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX210c
Description: 3 times a week, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX210c
Description: 3 times a week, for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 times a week, for 4 weeks
Study: NCT05803161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Congrong Runtong oral liquid
Description: Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Congrong Runtong oral liquid
Description: Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placental Congrong Runtong oral liquid
Description: Placental Congrong Runtong oral liquid
Study: NCT04639232

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prob-milk
Description: Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Voluntas-Prob
Description: Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
Study: NCT04842630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1916
Description: All participants receive SHR-1906 alone
Study: NCT05161000

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary counseling
Description: dietary counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Description: dietary counseling
Study: NCT06465550

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD211
Description: Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
Study: NCT06236178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: 1 ml of 40 mg methylprednisolone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: 1 ml of 40 mg methylprednisolone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Blood
Description: 1 ml of autologous venous blood

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Blood
Description: 1 ml of autologous venous blood
Study: NCT06152094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BP Activate Letter
Description: Participants in the BP Activate Letter arm will receive a BP Activate Report that includes personalized details about recent measurements, current medications, and computer-generated medication recommendations that might improve your blood pressure, along with a log for tracking additional SMBP measurements. They will also receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Letter
Description: Participants in the Control Letter arm will receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.
Study: NCT05906069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Description: The intervention will consist in a structured internet-based intervention with 10 modules that will combine cognitive-behavioral techniques to improve obsessive-compulsive symptoms as well as the emotion regulation ability.
Study: NCT06027034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online program for psoriasis (GAIA-PSO-01)
Description: The program to-be-tested (GAIA-PSO-01) is an interactive online program for independent use by users with psoriasis. It focuses on recognized treatment elements of cognitive behavioral therapy (CBT) and behavior change techniques.
Study: NCT05451303

Intervention type: DEVICE
Intervention: OralViome Cancer Testing System
Description: The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.
Study: NCT05993312

Intervention type: OTHER
Intervention: quality of life
Description: To describe the relationship between distant sequelae of trauma assessed by the GOSE scale and quality of life
Study: NCT05451303

Intervention type: DEVICE
Intervention: OralViome Cancer Testing System
Description: The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.

Intervention type: DEVICE
Intervention: OralViome Cancer Testing System
Description: The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.
Study: NCT06236178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic
Description: 1 ml of 2% prilocaine HCl
Study: NCT05889247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA treatment monitoring
Description: A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)
Study: NCT05320822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehab (Group 2)
Description: The Active Rehab protocol builds off of initial chief complaints and duty profile and addresses symptom control followed by a progressive and prescribed integration of activities to full return to duty that should be integrated with the current PRA TBICoE protocols. The specific activity areas in the intervention include low-intensity aerobic exercise that does not exacerbate symptoms, cognition, balance, visual/vestibular, and comfort/ general well-being.~Participants can be progressed daily according to symptom limitations. At least 3-4 sessions each week are recommended based on a trial of sport-related mTBI and other interventions of this type concerning mTBI/concussion. During each phase, low level aerobic exercise that does not significantly exacerbate symptoms, such as nature walks, will be recommended. The additional activity types that may be chosen include cognitive, balance, visual/vestibular, and comfort/general well-being.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Return to Activity (Group 1)
Description: Participant will be asked to use symptoms to guide activity from the time of the injury until participant is asymptomatic. Once asymptomatic, participant will begin the PRA TBICoE clinical recommendation. During this time clinicians will document activities in each stage in addition to initial symptom checklist, stage of PRA CoE progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
Study: NCT06236178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic
Description: 1 ml of 2% prilocaine HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic
Description: 1 ml of 2% prilocaine HCl
Study: NCT06124144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleylphosphocholine
Description: The trial is a dose escalation trial that follows a 3+3 approach. The sample size is determined by a decision-making algorithm and by the tolerability of the study drug in the study participants. This design follows predetermined rules that help identify notable toxicities in time with a reasonable degree of accuracy. The initial dose will be 50mg OlPC (1 capsule) and participants in subsequent cohorts will receive 100mg (2 capsules), 150mg (3 capsules), 200mg (4 capsules), 250mg (5 capsules), or 300mg (6 capsules) if the previous doses are tolerated. The study ends when the last cohort is completed or when it is determined that a dose (within a cohort) is not tolerable.
Study: NCT05253053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420
Description: TT-00420 tablet will be administered orally once daily per protocol defined schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420
Description: TT-00420 tablet will be administered orally once daily per protocol defined schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420
Description: TT-00420 tablet will be administered orally once daily per protocol defined schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Product: Atezolizumab
Description: Atezolizumab would be administered via infusion on Day 1 of 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Product: Nab-Paclitaxel
Description: Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle
Study: NCT05241496

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration
Description: Lidocaine in spray form is a simple and convenient local anaesthetic with minimal adverse effects and is often used in dentistry for oral mucosal anaesthesia during minor surgical interventions. The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration. Lidocaine acts by stabilization of the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action (Hüseyin Aksoy et al. ,2016 ) .
Study: NCT03981211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
Description: 8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
Description: 8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
Description: 4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily